Altered regulation of tau phosphorylation in a mouse model of down syndrome aging

被引:43
|
作者
Sheppard, Olivia
Plattner, Florian
Rubin, Anna
Slender, Amy [2 ]
Linehan, Jacqueline M.
Brandner, Sebastian
Tybulewicz, Victor L. J. [2 ]
Fisher, Elizabeth M. C.
Wiseman, Frances K. [1 ]
机构
[1] UCL, Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England
[2] MRC Natl Inst Med Res, London, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Alzheimer disease; Down syndrome; Tau; DYRK1A; GSK-3; beta; Phosphorylation; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN-DEPENDENT KINASE-5; PROTEIN PHOSPHATASES PP1; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; NEUROFIBRILLARY DEGENERATION; TC1; MOUSE; HUMAN BRAIN; SYNAPTIC PLASTICITY; HYPERPHOSPHORYLATION;
D O I
10.1016/j.neurobiolaging.2011.06.025
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Down syndrome (DS) results from trisomy of human chromosome 21 (Hsa21) and is associated with an increased risk of Alzheimer's disease (AD). Here, using the unique transchromosomic Tc1 mouse model of DS we investigate the influence of trisomy of Hsa21 on the protein tau, which is hyperphosphorylated in Alzheimer's disease. We show that in old, but not young, Tc1 mice increased phosphorylation of tau occurs at a site suggested to be targeted by the Hsa21 encoded kinase, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A). We show that DYRK1A is upregulated in young and old Tc1 mice, but that young trisomic mice may be protected from accumulating aberrantly phosphorylated tau. We observe that the key tau kinase, glycogen synthase kinase3-beta (GSK-3 beta) is aberrantly phosphorylated at an inhibitory site in the aged Tc1 brain which may reduce total glycogen synthase kinase3-beta activity. It is possible that a similar mechanism may also occur in people with DS. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation
    Hundelt, M.
    Fath, T.
    Selle, K.
    Oesterwind, K.
    Jordan, J.
    Schultz, C.
    Goetz, J.
    von Engelhardt, J.
    Monyer, H.
    Lewejohann, L.
    Sachser, N.
    Bakota, L.
    Brandt, R.
    NEUROBIOLOGY OF AGING, 2011, 32 (06) : 991 - 1006
  • [2] Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells
    Rachubinski, Angela L.
    Maclean, Kenneth N.
    Evans, Jeffrey R.
    Bjugstad, Kimberly B.
    EXPERIMENTAL GERONTOLOGY, 2012, 47 (09) : 723 - 733
  • [3] A mouse model to study tau pathology related with tau phosphorylation and assembly
    Engel, Tobias
    Lucas, Jose J.
    Hernandez, Felix
    Avila, Jesus
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 257 (1-2) : 250 - 254
  • [4] Turning down tau phosphorylation
    Peter M Fischer
    Nature Chemical Biology, 2008, 4 : 448 - 449
  • [5] Turning down tau phosphorylation
    Fischer, Peter M.
    NATURE CHEMICAL BIOLOGY, 2008, 4 (08) : 448 - 449
  • [6] Tau Phosphorylation in a Mouse Model of Temporal Lobe Epilepsy
    Alves, Marianna
    Kenny, Aidan
    de Leo, Gioacchino
    Beamer, Edward H.
    Engel, Tobias
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [7] Oxidative stress and tau phosphorylation in the brain from Werner mice, a premature aging disorder mouse model
    Paka, G. Djiokeng
    Arseneault, M.
    LeBei, M.
    Ramassamy, C.
    MOLECULAR BIOLOGY OF THE CELL, 2013, 24
  • [8] Endosomal structure and APP biology are not altered in a preclinical mouse cellular model of Down syndrome
    Cannavo, Claudia
    Cleverley, Karen
    Maduro, Cheryl
    Mumford, Paige
    Moulding, Dale
    Fisher, Elizabeth M. C.
    Wiseman, Frances K.
    PLOS ONE, 2022, 17 (05):
  • [9] Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome
    Mitra, Ananya
    Blank, Martina
    Madison, Daniel V.
    BRAIN RESEARCH, 2012, 1440 : 1 - 8
  • [10] Identification of Molecules with Altered Expression in the Brain of Mouse Model for Down Syndrome by Comprehensive Analyses
    Ishihara, Keiichi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2013, 133 (09): : 989 - 994